This week in therapeutics




Licensing status

Publication and contact information


Parkinson's disease (PD)

PTEN induced putative kinase 1 (PINK1)

In vitro and cell culture studies suggest activating PINK1 could help treat PD. A PINK1 loss-of-function mutation leads to early onset PD. In vitro, a modified ATP called N6 furfuryl ATP (KTP) activated PINK1. In cultured human cells, the cell-permeable KTP precursor kinetin increased phosphorylation of PINK1 substrates compared with adenine, which protected cells from stress-induced apoptosis. Next steps include testing kinetin in rat and fly models of PD (see All in the family, page 5).

SciBX 6(35); doi:10.1038/scibx.2013.970
Published online Sept. 12, 2013

Method of use for kinetin patented; licensed to Mitokinin LLC

Hertz, N.T. et al. Cell; published online Aug. 15, 2013;
Contact: Kevan M. Shokat, University of California, San Francisco, Calif.